Cargando…

Role of Pegylated Interferon in Patients with Chronic Liver Diseases in the Context of SARS-CoV-2 Infection

The coronavirus 2019 (COVID-19) pandemic has resulted in 168 million cases and about 3.5 million deaths (as of May 26, 2021) during the last 18 months. These 18 months of the COVID-19 pandemic have been characterized by phases or waves of new cases, the emergence of new variants of the deadly virus,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akbar, Sheikh MF, Mahtab, Mamun A, Aguilar, Julio C, Uddin, Md H, Khan, Md Sakirul I, Yoshida, Osamu, Penton, Eduardo, Gerardo, Guillen N, Hiasa, Yoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Jaypee Brothers Medical Publishers 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286362/ https://www.ncbi.nlm.nih.gov/pubmed/34316461 http://dx.doi.org/10.5005/jp-journals-10018-1341

Ejemplares similares

Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon
por: Al-Mahtab, Mamun, et al.
Publicado: (2023)

The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment
por: Al Mahtab, Mamun, et al.
Publicado: (2023)

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)
por: Al Mahtab, Mamun, et al.
Publicado: (2018)

Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2023)

Nobel Prize for the Discovery of Hepatitis B and C: A Brief History in Time
por: Al-Mahtab, Mamun, et al.
Publicado: (2020)

Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Nature of Host Immunity during Hepatitis B Virus Infection and designing Immune Therapy
por: MF Akbar, Sheikh, et al.
Publicado: (2018)

High Prevalence of Wilson's Diseases with Low Prevalence of Kayser–Fleischer Rings among Patients with Cryptogenic Chronic Liver Diseases in Bangladesh
por: Choudhury, Nuzhat, et al.
Publicado: (2019)

Prevalence of Hepatitis B Virus and Hepatitis C Virus in a Tea Garden of Bangladesh
por: Al Mahtab, Mamun, et al.
Publicado: (2017)

Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh
por: Islam, Md Azizul, et al.
Publicado: (2020)

Effect of Granulocyte Colony-stimulating Factor and Erythropoietin on Patients with Acute-on-chronic Liver Failure
por: Haque, Md Nazmul, et al.
Publicado: (2020)

Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2023)

Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh
por: Bhuyan, Muhammad AR, et al.
Publicado: (2020)

Risk of congenital birth defects during COVID-19 pandemic: Draw attention to the physicians and policymakers
por: Khan, Md Sakirul Islam, et al.
Publicado: (2020)

Healthcare for non-Covid-19 liver disease patients during the Covid-19 pandemic in Bangladesh: Current trend and future implications
por: Faizul Huq, A. K. M., et al.
Publicado: (2020)

Reply to “Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19”
por: Khan, Md. Saiful Islam, et al.
Publicado: (2021)

Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19
por: Khan, Md. Saiful Islam, et al.
Publicado: (2020)

Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19
por: Khan, Md. Saiful Islam, et al.
Publicado: (2020)

Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure
por: Hossain, Sharker M. S., et al.
Publicado: (2021)

Unprecedented rise of monkeypox in Europe and America: Are Asian countries ready for a new outbreak during the ongoing COVID-19 pandemic?
por: Khan, Sakirul, et al.
Publicado: (2022)

Immune therapies against chronic hepatitis B
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Stem Cell Therapy for Cirrhosis of Liver in Bangladesh: Specific Design Compatible for Developing Country
por: Al Mahtab, Mamun, et al.
Publicado: (2018)

Recent downhill course of COVID-19 at Rohingya refugee camps in Bangladesh: Urgent action solicited
por: Khan, Sakirul, et al.
Publicado: (2021)

Dengue Infections during COVID-19 Period: Reflection of Reality or Elusive Data Due to Effect of Pandemic
por: Khan, Sakirul, et al.
Publicado: (2022)

Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
por: Malakar, Debraj, et al.
Publicado: (2021)

Clinical Manifestations of Hospitalized COVID-19 Patients in Bangladesh: A 14-day Observational Study
por: Shaha, Modhusudon, et al.
Publicado: (2021)

Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation
por: Al Mahtab, Mamun, et al.
Publicado: (2019)

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
por: Shiraishi, Kana, et al.
Publicado: (2023)

Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study
por: Faizul Huq, AKM, et al.
Publicado: (2020)

Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure
por: Manik, Abul H, et al.
Publicado: (2021)

Therapeutic Endoscopy during COVID-19 Pandemic: An Observational Study from Bangladesh
por: Al Mahtab, Mamun, et al.
Publicado: (2020)

Co-existence of a pandemic (SARS-CoV-2) and an epidemic (Dengue virus) at some focal points in Southeast Asia: Pathogenic importance, preparedness, and strategy of tackling
por: Khan, Sakirul, et al.
Publicado: (2022)

HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis
por: Fleites, Yoel A, et al.
Publicado: (2021)

Early Treatment with Pegylated Interferon Lambda for Covid-19
por: Reis, Gilmar, et al.
Publicado: (2023)

EDITORIAL
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2019)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3tl0v5kdavktbnmkjdhpa4n9tk